FRENADIN
FRENADIN
Active ingredient: Mebeverine hydrochloride 135 mg.
Dosage form: Film-coated tablet.
Packaging: Box of 3 blisters x 10 tablets.
Expiry date: 36 months.
Posology
Duration of use is not limited.
If one or more doses are missed, the patient should continue with the next dose as prescribed, the missed dose(s) should not be taken in addition to the regular dose.
Adults (including the elderly): One tablet three times a day, preferably 20 minutes before meals. After a period of several weeks, when the desired effect has been obtained, the dosage may be gradually reduced.
Paediatric population: Not recommended for use in children and adolescents below 18 years, due to insufficient data on safety and efficacy.
Special populations
No posology studies in elderly, renal and/or hepatic impaired patients have been performed. No specific risk for elderly, renal and/or hepatic impaired patients could be identified from available post-marketing data. No dosage adjustment is deemed necessary in elderly, renal and/or hepatic impaired patients.
Method of administration
For oral use.
The film coated tablets should be swallowed with a sufficient amount of water (at least 100 ml water).
INDICATIONS
For the symptomatic treatment of irritable bowel syndrome and other conditions usually included in this grouping such as: chronic irritable colon, spastic constipation, mucous colitis, spastic colitis.
Mebeverine is effectively used to treat the symptoms of these conditions such as: colicky abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence.
CONTRAINDICATIONS
Hypersensitivity to mebeverine hydrochloride or any component of the product.
